Molecular Mechanisms and Prognostic Factors in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) develops against a background of chronic liver injury, exhibiting extensive molecular heterogeneity and variable clinical outcomes. Tumourigenesis is driven by genetic alterations in key regulators—such as TP53, CTNNB1 and TERT—that converge on pathways controlling the cell cycle, apoptosis and DNA repair. Epigenetic modifications, notably DNA methylation and histone changes, shape aberrant transcriptional programmes, while metabolic reprogramming—characterised by enhanced glycolysis and altered lipid metabolism—supports rapid proliferation. The tumour microenvironment, comprising infiltrating immune cells, stromal elements and dysfunctional vasculature, modulates progression and therapeutic response. Integration of multi-omics datasets, including copy-number variation, methylation and transcriptomics, has generated prognostic classifiers that refine risk stratification and guide personalised management. Nevertheless, robust biomarkers and mechanistic insights remain essential to advance early detection and targeted treatment of HCC.

Research from Nature Portfolio

One investigation employed large-scale transcriptomic analysis to delineate diagnostic and prognostic markers. A five-gene signature emerged—CD69, CDC25B, MGMT, TOP2A and TXNIP—with CD69 expression positively correlating with T-cell infiltration and overall survival. This panel underscored dysregulation of cell cycle pathways and immunoinflammatory responses, alongside a global suppression of apoptosis in tumours. In a complementary multi-omics study, integration of DNA copy-number variation, methylation profiles and mRNA expression stratified HCC into three prognostic subtypes. The most aggressive subset, marked by stemness programmes and recurrent BAP1 mutations, highlighted the critical interplay between genomic and epigenomic alterations in defining patient outcomes and informing precision management strategies.

Molecular Mechanisms and Prognostic Factors in Hepatocellular Carcinoma publication trend

The graph below shows the total number of articles in molecular mechanisms and prognostic factors in hepatocellular carcinoma across all publications each year (not limited to Nature Index journals).

Technical terms

mTORC2: multi-protein kinase complex that regulates cell survival, metabolism and cytoskeletal organisation.

MicroRNA: short non-coding RNA molecule that modulates gene expression by targeting messenger RNA for degradation or translational repression.

LASSO regression: statistical method that performs feature selection by imposing a penalty on the absolute size of regression coefficients.

Copy-number variation: genomic alteration in which sections of the genome are duplicated or deleted, affecting gene dosage.

DNA methylation: epigenetic modification involving addition of methyl groups to cytosine bases, influencing gene transcription.

Tumour microenvironment: the local cellular and molecular milieu surrounding a tumour, including immune cells, fibroblasts and blood vessels.

References

1. CD69 serves as a potential diagnostic and prognostic biomarker for hepatocellular carcinoma. Scientific Reports (2023).
2. Integrative analysis of genomic and epigenomic regulation of the transcriptome in liver cancer. Nature Communications (2017).
3. Rictor mediates p53 deactivation to facilitate the malignant transformation of hepatocytes and promote hepatocarcinogenesis. Journal of Translational Medicine (2023).
4. Identification of subclusters and prognostic genes based on glycolysis/gluconeogenesis in hepatocellular carcinoma. Frontiers in Immunology (2023).